3 Healthcare Stock Stories For Weekend Investment Wellness

Pluristem Therapeutics (NASDAQ:PSTI): Closing price $2.98

Pluristem reported that it is expanding its presence in the orthopedic and sports medicine markets with plans to begin a Phase I clinical trial, through which to study the safety and efficacy of the local administration of PLX cells to patients suffering from injuries to tendons. This evaluation will consist of a randomized, double blind, placebo-controlled study to evaluate the safety and efficacy of local intra-tendon injections of PLX-PAD cells to patients suffering from rotator cuff tear requiring arthroscopic repair. The hypothesis is that PLX-PAD cells will improve the post-operative structural and functional status of the rotator cuff. This placebo-controlled evaluation will be conducted in around 30 patients with a follow-up period of six months.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

PSTI

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX): Closing price $85.67

Vertex has announced data from a Phase 2 study of VX-661 and ivacaftor that exhibited statistically significant improvements in lung function among adults suffering with cystic fibrosis, who have two copies (homozygous) of the most common mutation in the cystic fibrosis transmembrane conductance regulator gene, known as F508del. The study examined four dose levels of VX-661 (10, 30, 100 and 150 mg) dosed once daily for 28 days in combination with ivacaftor (150 mg) dosed twice daily. The study also evaluated a separate group of patients who received VX-661 (10, 30, 100 and 150 mg) dosed without ivacaftor for 28 days. As a result, dose-dependent, mean relative improvements in lung function (percent predicted forced expiratory volume in one second; FEV), both within group and versus placebo, were seen across the combination dosing groups.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

VRTX

Chembio Diagnostics (NASDAQ:CEMI): Closing $4.60

The firm says that the Clinical Laboratory Improvement Amendments waiver studies for its DPP HIV 1/2 Assay have begun. In December, Chembio received FDA clearance for the DPP HIV 1/2 assay, which detects antibodies to HIV 1 and 2 in oral fluid, finger-stick whole blood (fingerstick), venous whole blood, serum or plasma samples. The CLIA waiver studies are mandated by the FDA to establish the quality standards for laboratory testing, which ensures the accuracy, reliability and timeliness of patient tests results regardless of where the tests are performed.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

CEMI

Investing Insights: Do These Factors Support Arena Pharmaceuticals?

More Articles About:    

More from The Cheat Sheet